Brickell Biotech posts quarterly revenue gain on strength of Botanix deal
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported higher second-quarter revenue, largely on the strength of a recent asset-purchase agreement.
Brickell recorded revenue of $4.3 million, compared with $200,000 in the second quarter of 2021. Most of that — $3 million — came from an upfront payment from Botanix SB, a subsidiary of Botanix Pharmaceuticals Ltd., which acquired all of Brickell’s rights and assets to sofpironium bromide, a potential treatment for primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. Food and Drug Administration for sofpironium bromide gel in mid-2022.
Brickell will receive upfront and near-term regulatory milestone payments of up to $9 million from Botanix, with additional success-based regulatory and sales milestone payments of up to $168 million.
SPONSORED CONTENT
Solar Operations and Maintenance for Commercial Properties
One key qualification to consider when selecting a solar partner to install your system is whether they have an Operations and Maintenance (O&M) or service department. Since solar is a long-term asset with an expected lifecycle of 30 plus years, ongoing O&M should be considered up front. A trusted O&M partner will maximize your system’s energy output and therefor the return on your investment.
Brickell’s net loss for the second quarter totaled $1 million, down from $11.1 million in the same period a year ago.
The company in July effected a 1-for-45 reverse stock split to regain compliance with the Nasdaq Capital Market for minimum stock price. Brickell’s stock closed Thursday at $3.27.
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported higher second-quarter revenue, largely on the strength of a recent asset-purchase agreement.
Brickell recorded revenue of $4.3 million, compared with $200,000 in the second quarter of 2021. Most of that — $3 million — came from an upfront payment from Botanix SB, a subsidiary of Botanix Pharmaceuticals Ltd., which acquired all of Brickell’s rights and assets to sofpironium bromide, a potential treatment for primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. Food and Drug Administration for sofpironium bromide gel in mid-2022.
Brickell…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!